Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine dose-ranging pilot trial in high-risk acute non-disabling cerebrovascular events
ChiCTR2100050830Phase 4Recruiting
- Sponsor
- Liaocheng Third People's Hospital
- Start
- Aug 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of colchicine in ischemic stroke and transient ischaemic attack (TIA) (4 arms), sponsored by Liaocheng Third People's Hospital. Primary endpoints: High sensitivity C-reactive protein and Adverse events within 14 days. Started Aug 2021; status: recruiting.
02
Drugs
colchicine
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ChiCTR2100050830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050830.